A U.K. lab has a plan to make potential coronavirus vaccine available at lowest possible price


Imperial College London, which is about to launch a combined first and second phase of coronavirus vaccine testing on June 15, is aiming to make sure its product is available at the lowest possible price in the United Kingdom and several other countries if it proves to be safe and effective, The New York Times reports.
Scientists and health experts have called for any successful vaccine to be distributed at low cost with need prioritized over profit, but since major pharmaceutical companies and biotechnology startups have so far led the development race, it's unclear whether that will happen. The vaccine Imperial College is developing is reportedly cheap and easy to manufacture, so the university is creating a "social enterprise" in partnership with the Hong Kong-based investment firm Morningside Ventures called VacEquity Global Health. The company will be for-profit, but Imperial College has promised to make the vaccine available at the lowest possible cost in the U.K. and low- and middle-income countries. It may charge more for wealthier countries like the United States or Singapore, however.
Meanwhile, scientists are reportedly close to a breakthrough when it comes to antibody therapy, according to pharmaceutical company AstraZeneca. The potential treatment, which involves the injection of cloned antibodies that counteract COVID-19, could reportedly prove significant for people in the early stages of infection. If the treatment winds up being successful, it will be more expensive than vaccine production, so the therapy would likely be targeted at the elderly and other vulnerable people who may struggle to develop a "good response to a vaccine." Read more at The New York Times and The Guardian.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
How successful would Elon Musk's third party be?
Today's Big Question Musk has vowed to start a third party after falling out with Trump
-
Music reviews: Bruce Springsteen and Benson Boone
Feature "Tracks II: The Lost Albums" and "American Heart"
-
Why passkeys are the next frontier in digital security
A disruptive new technology promises to put passwords to bed forever — but not yet
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia